Skip to main content
Donate

Copyright

DART home

FAST-DART publishes both preprints and peer-reviewed articles. All articles posted and published by FAST-DART are made available under a No Copyright / CC0 Public Domain Dedication, unless expressly stated otherwise.

The author(s) who associate a work with FAST-DART dedicate the work to the public domain by waiving all copyright and related or neighboring rights worldwide, to the fullest extent permitted by applicable law. As a result, the work may be copied, modified, distributed, and performed, including for commercial purposes, without the need to seek permission.

This policy applies equally to manuscripts posted as preprints and to articles that have undergone peer review and are formally published by FAST-DART. Authors retain authorship and attribution, but do not retain exclusive copyright in FAST-DART–published content.

FAST Angelman Syndrome News

FAST Poland hosts second nationwide conference, "From Diagnosis to Therapy."

Measuring Communication in Angelman Syndrome to Support Better Trials

Celebrating Dr. David Segal: A Leader in Science and a Champion for Angelman Syndrome Research

International Angelman Day 2026: What Our Community Made Possible

FAST Leaders to Speak at the CNBC Cures Summit on Patient- and Family-Led Advocacy

AS Natural History Study Celebrates 20 Years!

Hope In Action: Angelman Community Delivers Big Wins in FY26 Fund Bill

Introducing Team Kick-AS, a new way to rally the Angelman syndrome community through running.

FAST COO Ryan Fischer Named 2026 Co-Chair of EveryLife Community Congress

Join Us on Capitol Hill: Advocate for Angelman Syndrome Research and Awareness

Call on Congress to Enact the FY2026 Defense Appropriations Act

An Update on the ION582 clinical development program including HALOS, REVEAL, and CHAMPION Trials

A Home Court for Hope: Drexel Women’s Basketball Champions Angelman Syndrome Awareness

How Heath’s Heroes Keep Turning a Day on the Course Into Research Progress

How One Night of Paddle Is Powering Angelman Syndrome Research

Voice of the Patient Report Submitted: A Powerful Milestone for the Angelman Syndrome Community

Trips for Tripp: A One-of-a-Kind Fundraiser With a Clear Goal

FAST × ASA Angelman Syndrome Clinical Trials Webinar: Europe/UK Sites, Eligibility, and How to Join Trials

Remi Cup: Driving for a Cure to Angelman Syndrome

Rewind, Press Play, Kick AS: A Party With a Bigger Purpose

FAST Poland hosts second nationwide conference, "From Diagnosis to Therapy."

Measuring Communication in Angelman Syndrome to Support Better Trials

Celebrating Dr. David Segal: A Leader in Science and a Champion for Angelman Syndrome Research

International Angelman Day 2026: What Our Community Made Possible

FAST Leaders to Speak at the CNBC Cures Summit on Patient- and Family-Led Advocacy

AS Natural History Study Celebrates 20 Years!

Hope In Action: Angelman Community Delivers Big Wins in FY26 Fund Bill

Introducing Team Kick-AS, a new way to rally the Angelman syndrome community through running.

FAST COO Ryan Fischer Named 2026 Co-Chair of EveryLife Community Congress

Join Us on Capitol Hill: Advocate for Angelman Syndrome Research and Awareness

Call on Congress to Enact the FY2026 Defense Appropriations Act

An Update on the ION582 clinical development program including HALOS, REVEAL, and CHAMPION Trials

A Home Court for Hope: Drexel Women’s Basketball Champions Angelman Syndrome Awareness

How Heath’s Heroes Keep Turning a Day on the Course Into Research Progress

How One Night of Paddle Is Powering Angelman Syndrome Research

Voice of the Patient Report Submitted: A Powerful Milestone for the Angelman Syndrome Community

Trips for Tripp: A One-of-a-Kind Fundraiser With a Clear Goal

FAST × ASA Angelman Syndrome Clinical Trials Webinar: Europe/UK Sites, Eligibility, and How to Join Trials

Remi Cup: Driving for a Cure to Angelman Syndrome

Rewind, Press Play, Kick AS: A Party With a Bigger Purpose

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.